Filing Flows › Companies › TG Therapeutics › Timeline
TG Therapeutics stock timeline
A year of the price with every insider trade, planned sale, earnings report and material 8-K marked
252 sessions+79.9% to $59.83
TG Therapeutics (TGTX) stock rose 80% over the last 252 sessions, to $59.83. On the way it reported 3 quarters, its insiders filed 2 open-market trades and 1 Form 144 notice of planned sales, and the company filed 1 material 8-K. Each is marked on the price and listed with what the stock did next.
Each mark, and what followed
| Date | Kind | What | Next session | 5 sessions | 21 sessions |
|---|---|---|---|---|---|
| Sep 10, 2026 | Form 144 | Form 144: Laurence N Charney plans to sell $275K | +1.3% (+1.9% vs SPY) | +2.2% (+3.3% vs SPY) | −2.4% (−4.2% vs SPY) |
| Sep 10, 2026 | Insider sale | Charney Laurence N sold $275K | +1.3% (+1.9% vs SPY) | +2.2% (+3.3% vs SPY) | −2.4% (−4.2% vs SPY) |
| Aug 3, 2026 | Earnings | Earnings: missed the EPS estimate by -88.6% | −11.9% (−13.4% vs SPY) | −4.5% (−7.9% vs SPY) | +4.3% (+1.6% vs SPY) |
| May 6, 2026 | Earnings | Earnings: missed the EPS estimate by -35.1% | +15.1% (+13.7% vs SPY) | +16.4% (+14.5% vs SPY) | +11.7% (+7.2% vs SPY) |
| Mar 20, 2026 | 8-K | Material definitive agreement | +1.3% (+0.2% vs SPY) | +5.4% (+7.7% vs SPY) | +18.8% (+10.6% vs SPY) |
| Feb 26, 2026 | Earnings | Earnings: missed the EPS estimate by -57.5% | +4.1% (+4.7% vs SPY) | −1.6% (−0.4% vs SPY) | +7.5% (+14.5% vs SPY) |
| Nov 24, 2025 | Insider sale | Echelard Yann sold $163K | +0.2% (−1.2% vs SPY) | −0.9% (−4.0% vs SPY) | −3.9% (−8.5% vs SPY) |
Insiders’ record here
In the year on the chart, TG Therapeutics' insiders reported 0 open-market buys ($0) and 2 sales ($438K). Of the 1 old enough to score, 1 were followed by the stock doing what the trade implied over the next 63 sessions (beating SPY after a buy, lagging it after a sale); the median excess return after a buy was — and after a sale −6.6%.
Across the whole universe (19,782 scored trades), insider buys beat the market 46% of the time and sales were followed by a lagging stock 61% of the time; buys of $1M or more 39%. Every pattern →
What this kind of 8-K usually did
| Item | 8-Ks | Next session, median | Up next session | 21 sessions, median | Typical size |
|---|---|---|---|---|---|
| 1.01 Material definitive agreement | 23,525 | 0.0% | 51% | +1.0% | ±1.4% |
| 2.03 New debt or off-balance-sheet obligation | 13,268 | 0.0% | 50% | +1.2% | ±1.3% |
Across every company in the move-odds universe, measured from the close before the filing. Every 8-K item ranked →
Report card: every quarter against the estimate → TG Therapeutics: every quarter → Live insider trades →
Prices are daily closes; filings and trades are as filed with the SEC (Form 4 within two business days of the trade, 8-K within four of the event). Moves after a mark are the stock's close-to-close change and the same for SPY; they describe the record, not what the next one will do. Not investment advice.